Production and initial evaluation of a humanized BsF(ab')(2) anti-CD3-based bispecific monoclonal antibody designed for therapy of human B-cell malignancies.

被引：0
|
作者：
Link, BK
Moes, R
Fusselman, WP
Kostelny, SA
Cole, MS
Tso, JY
Weiner, GJ
机构：
[1] UNIV IOWA,IOWA CITY,IA
[2] PROT DESIGN LABS,MT VIEW,CA
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1264 / 1264
页数：1
相关论文
共 50 条
  • [41] Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases
    Martinez-Chinchilla, Carlos
    Vazquez-Montero, Lucia
    Palazon-Carrion, Natalia
    Fernandez-Roman, Isabel M.
    Lopez-Barba, Jose
    De la Cruz-Merino, Luis
    Rodriguez-Bano, Jesus
    Palacios-Baena, Zaira R.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [42] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
    Lesokhin, Alexander M.
    Arnulf, Bertrand
    Niesvizky, Ruben
    Mohty, Mohamad
    Bahlis, Nizar J.
    Tomasson, Michael H.
    Rodriguez-Otero, Paula
    Quach, Hang
    Raje, Noopur S.
    Iida, Shinsuke
    Raab, Marc-Steffen
    Czibere, Akos
    Sullivan, Sharon
    Leip, Eric
    Viqueira, Andrea
    Leleu, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] A PHASE 1 STUDY OF CAL-101, AN ISOFORM-SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110D, IN COMBINATION WITH ANTI-CD20 MONOCLONAL ANTIBODY THERAPY AND/OR BENDAMUSTINE IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES
    Leonard, J.
    Schreeder, M.
    Coutre, S.
    Flinn, I.
    Wagner-Johnston, N.
    Devos, S.
    Boccia, R.
    Holes, L.
    Peterman, S.
    Miller, L.
    Yu, A.
    ANNALS OF ONCOLOGY, 2011, 22 : 137 - 137
  • [44] Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system
    Zhang, Huan
    Liu, Man
    Li, Qing
    Lyu, Cuicui
    Jiang, Yan-Yu
    Meng, Juan-Xia
    Li, Jing-Yi
    Deng, Qi
    LEUKEMIA & LYMPHOMA, 2022, 63 (02) : 353 - 361
  • [45] Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies
    Li, Ping
    Ge, Jian
    Ye, Shiguang
    Zhou, Lili
    Gong, Yiming
    Ruan, Huaying
    Kouros-Mehr, Hosein
    Liang, Aibing
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S592 - S593
  • [46] EVALUATION OF IMPACT OF PRIOR CAR T THERAPY ON PHARM ACOKIN ETICS (PK) AND PHARMACODYNAMICS (PD) OF ODRONEXTAMAB, A CD20 x CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/ REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Zhu, M.
    Meng, X.
    Brouwer-Visser, J.
    Yan, H.
    Conrado, D.
    Padros, M. Bravo
    Harnisch, L.
    Chaudhry, A.
    Mohamed, H.
    Ambati, S.
    Davis, J.
    Xu, X.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S65 - S65
  • [47] Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
    Bannerji, Rajat
    Allan, John N.
    Arnason, Jon E.
    Brown, Jennifer R.
    Advani, Ranjana
    Ansell, Stephen M.
    O'Brien, Susan M.
    Duell, Johannes
    Martin, Peter
    Joyce, Robin M.
    Li, Jingjin
    Flink, Dina M.
    Zhu, Min
    Weinreich, David M.
    Yancopoulos, George D.
    Sirulnik, Andres
    Chaudhry, Aafia
    Ambati, Srikanth R.
    Topp, Max S.
    BLOOD, 2020, 136
  • [48] Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
    Bannerji, Rajat
    Arnason, Jon E.
    Advani, Ranjana H.
    Brown, Jennifer R.
    Allan, John N.
    Ansell, Stephen M.
    Barnes, Jeffrey A.
    O'Brien, Susan M.
    Chavez, Julio C.
    Duell, Johannes
    Rosenwald, Andreas
    Crombie, Jennifer L.
    Ufkin, Melanie
    Li, Jingjin
    Zhu, Min
    Ambati, Srikanth R.
    Chaudhry, Aafia
    Lowy, Israel
    Topp, Max S.
    LANCET HAEMATOLOGY, 2022, 9 (05): : E327 - E339
  • [49] The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody
    Maruyama, Shuhei
    Wada, Daiki
    Kanayama, Shuji
    Shimazu, Haruka
    Miyano, Yumiko
    Inoue, Akira
    Kashihara, Masami
    Okuda, Kazuyuki
    Saito, Fukuki
    Nakamori, Yasushi
    Ishii, Kazuyoshi
    Kuwagata, Yasuyuki
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [50] STIMULATION OF HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS WITH ANTI-CD3 MONOCLONAL-ANTIBODY VS IL2 - DISPARATE EFFECTS ON T-CELL-DEPENDENT B-CELL DIFFERENTIATION DESPITE SIMILAR EFFECTS ON GENERATION OF UNRESTRICTED CYTOLYTIC ACTIVITY
    STOHL, W
    ELLIOTT, JE
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1992, 65 (01): : 30 - 38
12345